THE FUTURE, - Solvay

Performance
improvement
36
Performance improvement > INNOVATIONS 09
209822 209823 209826
NEW IMPROVED MANUFACTURING
EXECUTION SYSTEMS (MES): INFORMATION
TECHNOLOGY TO THE RESCUE
A new model for a better
performance
THE PROJECT. For many years, Manufacturing
Execution Systems (MES) have been used to run
manufacturing processes on the shop fl oor but
not without diffi culty or problems regarding
security and business continuity. Key issues for
any MES system are availability, performance,
business continuity, safety, security, GxP
compliance, and fl exibility.
Our multidisciplinary team involved the vendor in
a visionary and open minded approach, which
resulted in the development of an innovative and
robust model for the infrastructure of MES and
automation in general. It has been presented at
congresses and is also applicable to new
developments in equipment and systems across
other areas. It is fully validated and is being
replicated in other Solvay sites.
PHARMACEUTICALS SECTOR
> Marcel Degrutter; Roel Arents; Richard Bennink;
Francis Boulu; Erik Dehaan; Marcel Gross;
Hans Hamstra; Ben Hendriks; Ronald Top;
Erik Vandervoorden; Jan Westerbeek;
Bart Zondervan.
‘BREAKING THE LIMITS’: SUPPORTING
BUSINESS SUCCESS BY CREATING A FULLY
ENABLED ‘ON-DEMAND’ WEB 2.0 PHARMA
AFFILIATE
A better handling of
constant change
THE PROJECT. Our business faces constant
change, with internal needs and the external
environment in continuous fl ux. Improved
information sharing and collaboration between
ourselves and our partners are vital. We
re-engineered a Pharma sales affi liate into a fully
enabled on-demand organization using Web 2.0
best practices, processes, tools and technologies.
The system features are described and have
already been implemented. There are possibilities
for continued enhancements in the future. The
new IT platforms are able to handle constant
change in business needs and the environment.
Projects will deliver results more rapidly and in all
areas there will be less complexity.
PHARMACEUTICALS SECTOR
> Juergen Greilich; Bruce Boulanger;
Herbert Cramer; Benoit Lefeuvre; Johnathan Reid.
INNOVATIVE TECHNOLOGY FOR EARLIER
RELEASE OF THE CELL-BASED INFLUENZA
PRODUCT
No mercy on microbes
THE PROJECT. We designed a risk
assessment to identify the microbes that pose a
potential risk of entry into the infl uenza vaccine
manufacturing process. A new microbial
contaminant list was devised. Additionally
we used more effi cient technology (quantitative
polymerase chain reaction) to determine the
absence of the microbes from the vaccine
product.
The new testing yielded fi nancial and effi ciency
benefi ts: we saved over USD 400 000 annually.
We were able to release materials in time
for the Russian government to begin clinical trials,
and also in time for the American government
(PANDA Project) to begin their clinical trials.
PHARMACEUTICALS SECTOR
> Pier Hannah; Johan Boschloo; Robert Craig;
Michael Emery; Michael Hare; Sara Jackson;
Hans Kapteyn; Alex Kersten; Iris McLean;
Jeroen Medema; Maria Pagany;
Stephanie Passmore; Frauke Rueffer;
Pieter Schoen; Kenny Seaver; Melissa Stone;
Mathea Verkerk.